FDA Brief

Warning letters Biologics

FDA warning letter to

Blackfly Investments, LLC dba Molecular® Testing Labs

High riskIssued Oct 11, 2024Posted Oct 22, 2024Center for Biologics Evaluation and Research (CBER)

Blackfly Investments dba Molecular Testing Labs sells an HIV dried blood spot self-collection kit without FDA marketing authorization.

What happened

FDA reviewed the firm’s website (last reviewed October 1, 2024), prior correspondence, and other information. FDA found that MTL offers an HIV dried blood spot card self-collection kit for delivery to individuals, who are to self-collect samples and ship them to MTL for HIV testing. FDA says the kit has no approved PMA or IDE and no 510(k) notification, and that the firm continued to market it after FDA said it was not authorized.

What FDA found

  1. FDA says the HIV DBS card self-collection kit is a device because it is intended for use in diagnosing disease.

    FD&C Act §201(h)(1), 21 U.S.C. §321(h)(1)
  2. FDA says the kit is adulterated because it lacks an approved premarket approval application (PMA, FDA review for high-risk devices) or an approved investigational device exemption (IDE, permission to study an unapproved device).

    FD&C Act §501(f)(1)(B), 21 U.S.C. §351(f)(1)(B); §§515(a), 520(g)
  3. FDA says the kit is misbranded because the firm did not provide the required 510(k) premarket notification before commercial distribution.

    FD&C Act §502(o), 21 U.S.C. §352(o); §510(k), 21 U.S.C. §360(k)
  4. FDA says it has not authorized the kit for any use, including HIV serological diagnostic testing.

  5. FDA says the firm continued to market the kit after FDA told the firm it had no approved PMA, cleared 510(k), or approved IDE for it.

What FDA wants

FDA asks the firm to stop activities that cause misbranding or adulteration. Within 15 working days of receipt, the firm must notify FDA in writing of specific corrective steps, related documentation, and steps to prevent recurrence; if not complete, state the reason and completion date.

Who should pay attention

  • laboratories and test providers offering at-home HIV collection kits
  • companies selling or distributing self-collection diagnostic devices
  • regulatory teams at diagnostic labs and kit manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk